JUN 21, 2018 07:30 AM PDT

Keynote Presentation: Paving the Path Towards Precision Medicine in Inflammatory Bowel Diseases

C.E. CREDITS: P.A.C.E. CE | Florida CE
Speakers
  • Senior Director of Translational Research, Crohn's & Colitis Foundation
    Biography
      Dr. Andrés Hurtado-Lorenzo is the Senior Director of Translational Research at the Crohn's and Colitis Foundation. He is responsible for planning and oversight the Foundation's translational research portfolio that consist of a number research initiatives in the fields of: Precision Medicine, Genetics, Microbiome, Environmental Triggers, and Entrepreneurial Investing, a venture philanthropy initiative focused on accelerating product development in IBD. These initiatives aim to identify opportunities to translate observations in the laboratory and clinic into interventions that reach and benefit patients; from therapeutics and diagnostics to medical devices and procedures.

      Dr. Hurtado-Lorenzo is a translational scientist leader with previous proven success directing multidisciplinary teams focused on drug discovery and development for neurological diseases and rare diseases in the biotech and pharmaceutical industry (Wyeth, Pfizer, Proteostasis Therapeutics) from discovery to early clinical development. These efforts have resulted in the identification of candidate drugs currently evaluated in clinical trials.

      He obtained his Ph.D. in Molecular Medicine from the University of Manchester in the UK, where he pioneered work in the field of viral gene therapy for neurodegenerative diseases. He completed his postdoctoral work at Harvard Medical School, Massachusetts General Hospital and Columbia University, where he conducted groundbreaking research focused on molecular mechanisms of autophagy and other protein degradation pathways and their role in health and disease. His research has been published in books high impact factor publications like Nature Cell Biology and Nature Communications.

    Abstract:

    Crohn’s disease and ulcerative colitis also known as inflammatory bowel diseases or IBD, are characterized by chronic, recurrent inflammation of the gastrointestinal tract, which results from the interplay between genetic predisposition, altered immune response, intestinal microbial dysbiosis and environmental factors. The course of the disease is variable, with some patients having much more aggressive disease than others. Half of the patients will develop severe complications like strictures, fistulas and abscesses, which require surgery. In addition, some patients experience frequent relapses while others achieve prolonged remission without any additional therapy. Such variability in prognosis represents the difference between an excellent long-term outcome or progressive disability. Therefore, the main challenge in managing IBD is the early detection, ideally at diagnosis, of patients with potentially severe disease course and variability in treatment outcomes. Thus, if precision medicine is to be applied in IBD, it will require the stratification of patients with a high risk of relapse and complications, and better characterization of patients who may respond preferentially to specific therapies. In this presentation I will highlight current advances towards the integration of clinical and molecular phenotypes for early prediction of complicated disease course at diagnosis and response to biological therapy. I will also highlight the current efforts of the Crohn’s and Colitis Foundation to build the largest biorepository and research exchange platform called IBD Plexus, which aims to integrate longitudinal clinical data and patient reported outcomes from than 40,000 patients along with genetic and multi-omics profiles from 7,000 IBD patients, and how this platform will accelerate the path towards precision medicine in IBD.


    Show Resources
    You May Also Like
    MAY 24, 2018 09:30 AM PDT
    C.E. CREDITS
    MAY 24, 2018 09:30 AM PDT
    DATE: May 24, 2018 TIME: 9:30PM PDT The current gold standard in in vitro pre-clinical cancer treatment screening remain cell lines,...
    MAY 22, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 22, 2018 08:00 AM PDT
    DATE: May 22, 2018TIME: 08:00AM PDT The nuclear receptors pregnane X receptor (PXR) and constitutive androstane receptor (CAR) are closely related transcription factors that...
    MAY 03, 2018 11:00 AM PDT
    MAY 03, 2018 11:00 AM PDT
    DATE: May 3, 2018TIME: 11:00AM PDT, 2:00PM EDTWhile stress is one of the leading causes of neuropsychiatric disorders, the molecular underpinnings of how stress induces alterations in b...
    APR 27, 2018 10:00 AM PDT
    C.E. CREDITS
    APR 27, 2018 10:00 AM PDT
    DATE: April 27, 2018TIME: 10:00am PST, 1:00pm ESTGlioblastoma (GBM) and Medulloblastoma (MB) are the most common adult and paediatric brain tumours, both of which can have devastating c...
    AUG 15, 2018 08:00 AM PDT
    C.E. CREDITS
    AUG 15, 2018 08:00 AM PDT
    DATE: August 15, 2018TIME: 08:00AM PDT, 11:00AM EDTThe failure of current chemotherapeutic strategies in the fight against cancer can be largely attributed to the occurrence of drug res...
    MAY 02, 2018 08:00 AM PDT
    C.E. CREDITS
    MAY 02, 2018 08:00 AM PDT
    Immunohistochemistry protocols, which utilize antibodies to visualize proteins in tissue sections, have many steps that need optimized to prevent non-specific background effects, artifacts, o...
    Loading Comments...
    Show Resources